智通财经APP讯，欧林生物(688319.SH)发布公告，公司近期配合主管税务机关的工作对公司涉税事项 进行了自查，经自查，公司本次预补缴企业所得税税款共计约420万元。截至公告披露日，公司已完成 缴纳，主管税务机关未对该事项给予处罚。目前，相关事项尚在沟通与处理过程中，最终金额需税务机 关进一步认定。 ...

人民财讯12月4日电，欧林生物(688319)12月4日公告，公司近期配合主管税务机关的工作对公司涉税事 项进行了自查。经自查，公司预补缴企业所得税税款共计420.01万元。目前公司已完成缴纳，主管税务 机关未对该事项给予处罚。相关事项尚在沟通与处理过程中，最终金额需税务机关进一步认定。若上述 金额计入公司2025年当期损益，将对公司2025年度净利润造成影响。 （原标题：欧林生物：补缴企业所得税税款420.01万元） ...

格隆汇12月4日丨欧林生物(688319.SH)公布，近期配合主管税务机关的工作对公司涉税事项进行了自 查，现将有关情况公告如下： 经自查，公司本次预补缴企业所得税税款共计人民币4,200,108.27元。截至本公告披露日，公司已完成 缴纳，主管税务机关未对该事项给予处罚。目前，相关事项尚在沟通与处理过程中，最终金额需税务机 关进一步认定。 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-066 若上述金额计入公司 2025 年当期损益，将对公司 2025 年度归属于上市公司 股东的净利润将造成影响，最终请以 2025 年度经审计的财务报告为准。公司将根 据最终结果，依据《企业会计准则》进行相应会计处理，对公司具体会计期间净 利润的最终影响，请以公司经审计的财务报告为准。 截至目前，该事项未对公司日常生产经营活动产生重大影响。公司将持续关 注相关事项进展，并依据《上海证券交易所科创板股票上市规则》等法律法规的 要求，及时履行信息披露义务，敬请广大投资者注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都欧林生物科技股份有限公司(以下简称"公司")近期配合主管税务机关 的工作对公司涉税事项进行了自查，现将有关情况公告如下： 一、基本情况 经自查，公司本次预补缴企业所得税税款共计人民币 4,200,108.27 元。截至 本公告披露日，公司已完成缴纳，主管税务机关未对该事项给予处罚。目前，相 关事项尚在沟通与处理过程中，最终金额需税 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

- The report introduces two key tracking indicators: "Large Order Transaction Amount Proportion" and "Net Active Buy Amount Proportion" [7] - The "Large Order Transaction Amount Proportion" is designed to capture the buying behavior of large funds. It is calculated by identifying large orders from transaction data and computing the proportion of large buy orders' transaction amounts relative to the total daily transaction amount [7] - The "Net Active Buy Amount Proportion" reflects investors' active buying behavior. It is derived by distinguishing active buy and sell transactions from transaction data, calculating the net active buy amount (active buy amount minus active sell amount), and expressing it as a proportion of the total daily transaction amount [7] Factor Backtesting Results - For individual stocks, the top 10 stocks with the highest 5-day average "Large Order Transaction Amount Proportion" include Xinhua Du (90.6%, 99.2% percentile), Beichen Industrial (89.1%, 98.8% percentile), and Zhongyou Engineering (88.8%, 100.0% percentile) [9] - For individual stocks, the top 10 stocks with the highest 5-day average "Net Active Buy Amount Proportion" include Senying Windows (22.3%, 100.0% percentile), Huitong Group (20.0%, 100.0% percentile), and Yuandong Biotech (19.6%, 100.0% percentile) [10] - For broad-based indices, the 5-day average "Large Order Transaction Amount Proportion" ranges from 71.7% (Shanghai 50 Index) to 74.3% (China Securities 500 Index), while the "Net Active Buy Amount Proportion" ranges from -5.2% (Shanghai 50 Index) to 1.9% (China Securities 500 Index) [12] - For industries, the 5-day average "Large Order Transaction Amount Proportion" is highest in the banking sector (80.6%, 86.5% percentile) and lowest in the electronics sector (70.8%, 16.4% percentile). The "Net Active Buy Amount Proportion" is highest in the steel sector (7.9%, 75.8% percentile) and lowest in the banking sector (-14.6%, 3.3% percentile) [13] - For ETFs, the top 10 ETFs with the highest 5-day average "Large Order Transaction Amount Proportion" include Guotai CSI A500 ETF (92.3%, 36.1% percentile) and Guotai SSE 10-Year Treasury Bond ETF (90.7%, 89.3% percentile) [15] - For ETFs, the top 10 ETFs with the highest 5-day average "Net Active Buy Amount Proportion" include Southern SSE STAR Chip ETF (27.5%, 100.0% percentile) and E Fund Hang Seng Dividend Low Volatility ETF (23.6%, 99.6% percentile) [16]

Core Viewpoint - Oulin Biotech's stock has shown significant volatility, with a year-to-date increase of 136.79% and a recent decline of 2.03% on December 2, 2023, indicating fluctuating investor sentiment in the biotech sector [1] Company Performance - Oulin Biotech reported a revenue of 507 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 31.11% [2] - The net profit attributable to the parent company reached 47.48 million yuan, marking a substantial increase of 1079.36% compared to the previous year [2] - The company has distributed a total of 15.43 million yuan in dividends since its A-share listing [3] Stock Market Activity - As of December 2, 2023, Oulin Biotech's stock price was 25.10 yuan per share, with a market capitalization of 10.189 billion yuan [1] - The stock has experienced a trading volume of 49.39 million yuan with a turnover rate of 0.48% [1] - The stock has appeared on the "龙虎榜" (Dragon and Tiger List) twice this year, with the most recent occurrence on August 20 [1] Shareholder Information - As of September 30, 2025, Oulin Biotech had 10,200 shareholders, an increase of 56.42% from the previous period [2] - The average number of circulating shares per shareholder decreased by 36.07% to 39,746 shares [2] - Notable institutional shareholders include 兴全合润混合A and 兴全合宜混合A, with stable holdings compared to the previous period [3]

Core Viewpoint - Olin Bio is seeking to list on the Hong Kong Stock Exchange to become an "A+H" listed company, aiming to raise funds for innovative vaccine research and to reduce reliance on its core product, the adsorbed tetanus vaccine [1][5]. Group 1: Company Overview - Olin Bio, founded by industry veteran Fan Shaowen and his daughter Fan Fan, has become a key player in the vaccine market, particularly with its adsorbed tetanus vaccine, which has significantly contributed to its revenue [2][3]. - The company achieved a revenue of 589 million yuan in 2024, representing an 18.7% year-on-year increase, and a net profit of 20.76 million yuan, also up by 18.2% [3]. Group 2: Financial Performance - In the first half of 2025, Olin Bio reported a revenue of 306 million yuan, a 35.17% increase year-on-year, and a net profit of approximately 13.2 million yuan, marking a turnaround from previous losses [3]. - The adsorbed tetanus vaccine accounted for 90.99% of total revenue in 2024, with a sales revenue of 536 million yuan, indicating a 15.7% increase [3]. Group 3: Challenges and Risks - Olin Bio faces significant challenges, including a high dependency on the adsorbed tetanus vaccine, which has consistently contributed over 90% of its revenue, exposing the company to market fluctuations and competitive pressures [7]. - The company is also under financial strain, with negative cash flows from operating activities and substantial funding needs for ongoing vaccine development and international expansion [7]. - The competitive landscape is intensifying, with both price competition in traditional vaccines and technological competition in innovative vaccines, potentially compressing profit margins [7].

Core Viewpoint - Company Olin Bio (688319.SH) has submitted an application for a mainboard listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, aiming to leverage its strong market position in the vaccine sector [1][2] Group 1: Company Overview - Olin Bio is a biopharmaceutical company focusing on unmet medical needs in "super bacteria vaccines" and "adult vaccines" [2] - The company has three commercialized products: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine [2] - Olin Bio's Tetanus Toxoid Vaccine holds over 80% market share in China as of 2024 [2] Group 2: Financial Performance - Revenue for Olin Bio during the reporting period (2022-2025) was 5.47 billion, 4.94 billion, 5.86 billion, and 3.05 billion respectively, showing significant fluctuations [4] - The annual profit and total comprehensive income were 26.58 million, 11.44 million, 15.72 million, and 13.23 million respectively, with 2023 and 2024 figures lower than 2022 [4] - Gross profit margins were consistently high at 92.3%, 93.1%, 94%, and 92.3% over the same period [4] Group 3: Revenue Sources - A significant portion of Olin Bio's revenue comes from the Tetanus Toxoid Vaccine, contributing approximately 4.377 billion, 4.63 billion, 5.358 billion, and 2.683 billion during the reporting period, accounting for around 80% to 93.7% of total revenue [5]

Core Viewpoint - The article discusses the IPO application of Olin Biotech (688319.SH) for listing on the Hong Kong Stock Exchange, highlighting its commercialized products and market position in the vaccine sector [1][2][5]. Group 1: Company Overview - Olin Biotech is a biopharmaceutical company focusing on unmet medical needs in "super bacteria vaccines" and "adult vaccines" [5]. - The company has three commercialized products: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine [5][6]. Group 2: Market Position and Financial Performance - Olin Biotech's Tetanus Toxoid Vaccine holds over 80% market share in China as of 2024 [2][6]. - Revenue projections for 2024 are estimated at 586 million yuan, with significant contributions from the Tetanus Toxoid Vaccine, which accounted for approximately 87.9% of total revenue in the first half of 2025 [10]. - The company reported revenues of 547 million yuan, 494 million yuan, and 586 million yuan for 2022, 2023, and 2024 respectively, with a notable fluctuation in annual profits [9]. Group 3: Sales Network and Growth - As of November 18, Olin Biotech's sales network covers 30 provinces and municipalities in China, with over 2,000 direct commercial relationships established with district and county-level disease control centers [6]. - The company has supplied its vaccines to approximately 8,100 vaccination points across the country, including around 2,400 general hospitals [6]. Group 4: Shareholding Structure - After its A-share listing, Shanghai Wushan became the largest shareholder of Olin Biotech, holding approximately 14.83% of the issued share capital [7].